There are only a few clinical data on non-oncological procedures performed with the new HugoTM robot-assisted surgery (RAS) system. Robot-assisted simple prostatectomy (RASP) is a minimally invasive treatment option for benign prostatic hyperplasia, and it demonstrated equal early functional and better peri-operative outcomes as compared to open simple prostatectomy.
In this paper, we reported the first large series of RASP performed with HugoTM RAS system.
This video is a step-by-step description of two different techniques for RASP. We analyzed the data of 20 consecutive patients who underwent RASP at OLV Hospital (Belgium) between February 2022 and March 2023. Patients baseline characteristics, perioperative and pathological and one-month postoperative outcomes were reported, using the median (interquartile range [IQR]) and frequencies.
Median age (IQR) and preoperative PSA were 72 (67 - 76) years, and 7,7 (5,0 - 13,4) ng/ml, respectively. A total of 11 patients experienced an episode of preoperative acute urinary retention, and 8 men had an indwelling bladder catheter at the time of the surgery. No intraoperative complication occurred, and there was no need for conversion to open surgery. Median operative and console time were 165 (121 - 180) and 125 (101 - 148) minutes. On the first postoperative day the urethral catheter was removed in 80% of the patients. Median length of stay was 3 (3 - 4) days. Three patients had minor post-operative complications. On final pathology, median prostate volume was 120 (101-154) gr. On post-operative uroflowmetry, median Qmax and post-void residual (PVR) were 16 (13 - 26) ml/s and 15 (0 - 34) cc.
This series represents the first report of surgical outcomes of RASP executed with HugoTM RAS System. Awaiting study with longer follow-up, our study suggests that HugoTM RAS has multiple applications, and it can ensure optimal outcomes in non-oncological procedures.
Journal of endourology. 2023 Jul 26 [Epub ahead of print]
Adele Piro, Federico Piramide, Eleonora Balestrazzi, Marco Paciotti, Carlo Bravi, Maria Peraire, Gabriele Sorce, Marco Ticonosco, Nicola Frego, Silvia Rebuffo, Claudia Collà Ruvolo, Antonio Inferrera, Geert Naeyer, Ruben De Groote, Francesco Greco, Alexandre Mottrie
Università degli Studi di Modena e Reggio Emilia, 9306, Department of Urology, University of Modena and Reggio Emilia, Modena, Italy., San Luigi Gonzaga University Hospital, 9340, Department of Oncology, Division of Urology, Orbassano, Piemonte, Italy., IRCCS Azienda Ospedaliero-Universitaria di Bologna, 18508, Division of Urology, Bologna, Emilia-Romagna, Italy., Clinical Institute Humanitas, 9268, Department of Urology, Rozzano, Lombardia, Italy., ORSI Academy, Ghent, Belgium., Onze-Lieve-Vrouwziekenhuis, 37467, Dep. of Urology, Aalst, Oost-Vlaanderen, Belgium., IRCCS Ospedale San Raffaele, 9372, Unit of Urology, Division of Experimental Oncology, Urological Research Institute, Milano, Lombardia, Italy., University of Modena and Reggio Emilia, 9306, Urology, Modena, Emilia-Romagna, Italy., IRCCS Humanitas Research Hospital, 9268, Department of Urology, Rozzano, Lombardia, Italy., Policlinico San Martino Hospital, University of Genova, Department of Urology, Genova, Italy., University of Naples Federico II School of Medicine and Surgery, 478484, Department of Urology, Napoli, Italy., Centro Salute Uomo, Urology Unit, Bergamo, Italy; ., Onze-Lieve-Vrouwziekenhuis, 37467, Dep. of Urology, Aalst, Oost-Vlaanderen, Belgium; ., Onze-Lieve-Vrouwziekenhuis, 37467, Dep. of Urology, Aalst, BE 9300, Belgium; ., Centro Salute Uomo, Urology Unit, Bergamo, Italy; .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/37493565